Health Canada has granted approval for Biogen’s Skyclarys (omaveloxolone) to treat Friedreich’s ataxia (FA), a rare, ...

In addition, I think the recognition across all diseases where not everyone is going to be an expert in FA, and people can refer readily to tertiary care centers and even ordinary care centers that ...

At this point, there are several therapies which are coming along, a large trial called the ExRx trial, which included the nutraceutical, nicotinamide riboside has finished. The data are not yet ...

Bill Nye critiqued HHS chief Robert F. Kennedy Jr. and his views on science and vaccines at a STAT event in New York.

As the only approved treatment to address disease progression, SKYCLARYS addresses a long-standing gap in the care of Canadians living with Friedreich's ataxia Friedreich's ...

As the only approved treatment to address disease progression, SKYCLARYS addresses a long-standing gap in the care of Canadians living with Friedreich’s ataxia Friedreich’s ataxia is a rare, ...

Biogen Canada Inc. is pleased to announce that Health Canada has approved SKYCLARYS™ (omaveloxolone) for the treatment of Friedreich's ataxia (FA) in patients 16 years of age and older.2 This approval ...

Mirian Andino, 11, of Barnegat uses a motorized wheelchair to get around. Her parents need to raise $15,000 for a ...

Biogen’s Skyclarys is on course to becoming the first approved medicine for the inherited neurological disease Friedreich’s ataxia (FA) in the EU after it was recommended by the EMA’s human ...

Overall, serious neurological events were uncommon in children aged 0 to 5 years, but more likely in those less than 2 years of age.

Zeke is proud to be a Trinity Titan. His dad said a photo of two friends helping Zeke to the football field for a group picture shows the impact Zeke has had on his school and his community.